Jean Y. Tang MD PhD

Clinical Focus

• Skin Cancer
• Epidemiology
• Clinical Trial
• Dermatology
• Basal Cell Carcinoma

Honors and Awards

• Clinical Investigator Award, Damon Runyon (July 1 2011 - July 2014)
• K23 Career Development Award, National Institutes of Health (2009 - 2013)
• Health Services Investigator Award, American Skin Association (2009)
• KL2 Clinical and Translational Science Institute Career, National Institutes of Health (2006-2009)
• Young Investigator Award, Prevent Cancer Organization (2007-2009)

Professional Education

Postdoctoral Advisees

Yuka Asai

Community and International Work

• Xeroderma Pigmentosum in Underserved Populations, Guatemala City, Guatemala 

Internet Links

• Jean Tang Lab

Current Research Interests

My research focuses on finding new ways to treat and prevent non-melanoma skin cancer. I am committed to bringing laboratory-based insights to benefit our patients. I am interested in these questions:
1. How do we prevent skin cancer?
2. What is the relationship between sunlight, vitamin D, and skin cancer risk?
3. Can we target certain tumor signaling pathways (Hedgehog pathway) to treat basal cell carcinomas - the most common cancer in the US?

Clinical Trials

• Pilot Biomarker trial to evaluate the efficacy of Itraconazole in patients w/ Basal Cell Carcinomas Recruiting
• Pilot trial to evaluate the effect of vitamin D on melanocyte biomarkers Choose one

Publications

• Calcium plus vitamin D supplementation and the risk of nonmelanoma and melanoma skin cancer: post hoc analyses of the women's health initiative randomized controlled trial. Tang JY, Fu T, Leblanc E, Manson JE, Feldman D, Linos E, Vitolins MZ, Zeitouni NC, Larson J, Stefanick ML. J Clin Oncol. 2011; 29 (22): 3078-84
• Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: women's health initiative randomized trials. Tang JY, Spaunhurst KM, Chlebowski RT, Wactawski-Wende J, Keiser E, Thomas F, Anderson ML, Zeitouni NC, Larson JC, Stefanick ML. J Natl Cancer Inst. 2011; 103 (19): 1469-75
• Targeting superficial or nodular Basal cell carcinoma with topically formulated small molecule inhibitor of smoothened. Tang T, Tang JY, Li D, Reich M, Callahan CA, Fu L, Yauch RL, Wang F, Kotkow K, Chang KS, Shpall E, Wu A, Rubin LL, Marsters JC, Epstein EH, Caro I, de Sauvage FJ. Clin Cancer Res. 2011; 17 (10): 3378-87
• Vitamin D3 inhibits hedgehog signaling and proliferation in murine Basal cell carcinomas. Tang JY, Xiao TZ, Oda Y, Chang KS, Shpall E, Wu A, So PL, Hebert J, Bikle D, Epstein EH. Cancer Prev Res (Phila). 2011; 4 (5): 744-51
• Reliability and prevalence of digital image skin types in the United States: results from National Health and Nutrition Examination Survey 2003-2004. Keiser E, Linos E, Kanzler M, Lee W, Sainani KL, Tang JY. J Am Acad Dermatol. 2012; 66 (1): 163-5